...
首页> 外文期刊>Human Pathology >An update on clinicopathological, immunohistochemical, and molecular profiles of colloid carcinoma of the lung
【24h】

An update on clinicopathological, immunohistochemical, and molecular profiles of colloid carcinoma of the lung

机译:肺胶体癌的临床病理,免疫组织化学和分子谱的最新进展

获取原文
获取原文并翻译 | 示例
   

获取外文期刊封面封底 >>

       

摘要

Colloid carcinoma is a rare subtype of lung adenocarcinoma characterized by abundant pools of extracellular mucin and scant malignant epithelium. Because of the rarity of these tumors, many of the reported clinicopathological and immunohistochemical characteristics are contradictory. Moreover, the molecular alterations that underlie these tumors are unknown. We present the clinicopathological, immunohistochemical, and molecular features of 13 cases of colloid carcinoma of the lung. The patients were 9 women and 4 men between the ages of 48 and 86 years. Surgical resection and staging were performed in all patients. Seven patients were in stage T1N0M0, 3 in T2N0M0, 2 in T2N1M0, and 1 in T2N0M1. The tumor was 100% mucinous in 9 patients, whereas in 4 cases, the lesions consisted of 50% to 90% mucin pools with the remainder being a noncolloid adenocarcinoma component ranging in morphology from bronchioalveolar to acinar, papillary, solid, or mixed patterns. Follow-up ranged from 35 to 128 months. Three patients died, 1 of disease and 2 of unrelated causes. The remaining 10 patients are alive at the time of reporting, 3 with recurrent disease. Immunohistochemical studies showed CK7, CK20, and CDX2 expression in all tumors, whereas TTF-1, surfactant A, and napsin A were not present or were only focally positive in most cases. Analysis showed KRAS mutations in 2 cases. All tumors were negative for ALK gene rearrangement and EGFR mutation. Our study highlights the clinicopathological, immunohistochemical, and molecular features of lung colloid adenocarcinoma and attempts,to clarify some misconceptions regarding this rare tumor. (C) 2015 Elsevier Inc. All rights reserved.
机译:胶体癌是一种罕见的肺腺癌亚型,其特征是大量的细胞外黏蛋白和少量的恶性上皮。由于这些肿瘤的稀有性,许多报道的临床病理和免疫组织化学特征是矛盾的。而且,未知这些肿瘤的分子改变。我们介绍了13例肺胶体癌的临床病理,免疫组织化学和分子特征。患者为9名女性和4名男性,年龄在48至86岁之间。所有患者均进行了手术切除和分期。 7例患者处于T1N0M0期,T2N0M0 3例,T2N1M0 2例,T2N0M1 1例。 9例患者的肿瘤为100%粘液性,而4例中,病变由50%至90%的粘蛋白池组成,其余为非胶体腺癌成分,形态从支气管肺泡到腺泡,乳头状,实心或混合型。随访时间为35到128个月。 3例患者死亡,1例疾病死亡,2例无关原因死亡。其余10例患者在报告时还活着,其中3例患有复发性疾病。免疫组织化学研究显示,CK7,CK20和CDX2在所有肿瘤中均表达,而在大多数情况下,TTF-1,表面活性剂A和棉素A均不存在或仅呈局部阳性。分析显示有2例发生KRAS突变。所有肿瘤的ALK基因重排和EGFR突变均为阴性。我们的研究突出了肺胶体腺癌的临床病理,免疫组织化学和分子特征,并试图阐明关于这种罕见肿瘤的一些误解。 (C)2015 Elsevier Inc.保留所有权利。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号